EMEA-000279-PIP01-08-M05
Key facts
Invented name |
Isentress
|
Active substance |
Raltegravir
|
Therapeutic area |
Infectious diseases
|
Decision number |
P/0155/2016
|
PIP number |
EMEA-000279-PIP01-08-M05
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of human immunodeficiency virus (HIV-1) infection
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Merck Sharp & Dohme (Europe) Inc.
Tel.: +33180464738 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-000279-PIP01-08-M05
|
Compliance opinion date |
19/06/2017
|
Compliance outcome |
positive
|